WASHINGTON — While there has been a recent increase among Medicare recipients in genomic testing that helps match cancer patients to the most effective treatment for their tumor, many Medicare beneficiaries with cancer are still not receiving next-generation sequencing (NGS), according to a new analysis by Georgetown University researchers.

The study appeared in JAMA Network Open on July 29, 2026. (“Genomic Testing Update Among Medicare Beneficiaries with Cancer”)

“Genomic testing is essential for matching cancer patients to the most effective targeted therapies,” says the study’s lead author So‑Yeon Kang, PhD, MBA, MPH, assistant professor of Health Management and Policy at Georgetown University’s School of Health. “While genomic testing became much more common among Medicare beneficiaries between 2016 and 2023, uptake of advanced next-generation sequencing genomic testing remained relatively low, suggesting that many patients may still not be benefiting from precision medicine.”

Medicare’s expanded coverage for NGS testing in 2018 for non-inherited tumor (somatic) mutations and the addition of coverage for inherited (germline) mutations in 2020, marking critical milestones in expanding access to genomic testing.

Before Medicare’s expanded coverage for NGS, coverage for genomic testing was limited and inconsistent. Earlier genomic testing often examined only one or a few genes at a time, whereas NGS testing can analyze many cancer-related genes simultaneously in a single test, helping physicians identify targeted treatment options more efficiently.

Using data from the Medicare Chronic Conditions Data Warehouse, the researchers examined the claims of nearly 400,000 beneficiaries age 66 and older diagnosed with lung, breast, colorectal, prostate or endometrial cancer filed from 2016 through 2023. The analysis tracked the use of both NGS and non‑NGS genomic testing before and after the coverage decisions.

Overall use of genomic testing among Medicare cancer patients remained relatively low. However, uptake nearly tripled from 6% in 2016 to 16.7% in 2023 following Medicare’s coverage decisions. The largest increase occurred among individuals with lung cancer, where NGS testing is the predominant genomic testing approach. In contrast, breast cancer patients continued to rely more heavily on non‑NGS genomic tests, reflecting differences in clinical practice and test availability.

The study also uncovered differences in testing uptake. Rates varied by age, race, ethnicity and geography, suggesting that factors beyond insurance coverage — such as provider awareness, regional resources, and patient education — may continue to influence who receives genomic testing.

“One limitation of our study is that we cannot directly compare Medicare with the overall U.S. population because our analysis included only older adults enrolled in traditional Medicare,” says Kang. “However, one finding that surprised our team was that NGS use and the growth in its uptake remained quite low across all five cancer types we studied, despite national Medicare coverage for these tests. This suggests that insurance coverage alone may not be sufficient to ensure broad adoption of precision medicine.”

Kang said that genomic testing is evolving rapidly as new targeted therapies and clinical evidence emerge. The authors recommend further research to evaluate how increased testing translates into improved outcomes and cost‑effectiveness. They also urge policymakers to consider how coverage policies can support the adoption of other emerging precision medicine technologies.

“Our next goal is to understand why genomic testing, and more specifically, NGS, remains underused and why uptake differs across cancer types and regions. We also plan to study whether receiving genomic testing ultimately leads to greater use of precision therapies and better patient outcomes,” concludes Kang.

###

This work was supported by the National Institute for Health Care Management Foundation.

In addition to Kang, study researchers include Rui Zhang, Chul Kim, Marc D. Schwartz, Jaeil Ahn, Arnold L. Potosky, and Carole Roan Gresenz, all from Georgetown University.

Kang reports receiving fees from the Colorado Consumer Health Initiative, Genentech, and Garner Health.

Journal

JAMA Network Open

Funder

National Institute for Health Care Management Foundation

DOI

10.1001/jamanetworkopen.2026.26078

At the heart of this revolution is CRISPR’s unique capability for sequence-specific targeting of DNA and RNA, offering an unprecedented modular and programmable approach. Initially confined to research laboratories, these gene-editing tools have rapidly advanced toward clinical translation, promising to redefine diagnostics and therapeutics alike. Functional genomics powered by CRISPR enables researchers to decipher unexpected cancer dependencies and resistance mechanisms by systematically interrogating the cancer genome. This granular insight is crucial in designing more effective and durable interventions.

On the diagnostic front, CRISPR-based platforms convert precise nucleic acid recognition into rapid mutation detection assays. These assays can discern tumor-specific genetic alterations, including single-nucleotide variants and complex fusion junctions, with remarkable speed and sensitivity. Such innovations could dramatically shorten the time from biopsy to tailored treatment decision, enhancing personalized medicine’s promise.

Therapeutically, CRISPR facilitates both ex vivo and in vivo strategies. Ex vivo techniques engineer immune cells to enhance their tumor-targeting efficacy, such as modifying T cells to better recognize and attack cancer cells. Meanwhile, nascent in vivo approaches aim to directly edit tumor-related sequences within the patient, targeting mutations that drive malignancy at their source. These interventions, though still early in development, open avenues toward truly precision-guided oncologic therapies.

Despite these exciting prospects, significant hurdles remain. Effective delivery of CRISPR components to cancer cells in vivo is a formidable challenge, often complicated by the tumor microenvironment and immune barriers. Moreover, safety concerns regarding off-target effects and unintended genomic alterations continue to prompt rigorous scrutiny. Addressing these technological limitations is essential to ensure patient safety and therapeutic efficacy.

Regulatory frameworks also lag behind scientific innovation, necessitating the establishment of clear guidelines for CRISPR-based diagnostics and therapies. Balancing rapid clinical adoption with comprehensive safety evaluations will be key to implementing these technologies on a broader scale.

Ultimately, CRISPR’s integration into oncology represents more than just a new set of tools—it signifies a paradigm shift. By bridging molecular diagnostics with novel therapeutic strategies, CRISPR technologies embody the next generation of personalized cancer care. As research progresses from bench to bedside, the promise of durable and precise cancer control becomes increasingly attainable.

The ongoing intersection of CRISPR innovation and clinical oncology offers a hopeful horizon, where genetic intricacies of cancer can be not only understood but precisely edited, heralding transformative impacts on patient outcomes.

Subject of Research: Advances and applications of CRISPR technology in clinical oncology, spanning molecular diagnostics, functional genomics, and therapies.

Article Title: CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics.

Article References:
Grigg, S., Shembrey, C., Fareh, M. et al. CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics. Nat Rev Clin Oncol (2026). https://doi.org/10.1038/s41571-026-01179-2

Image Credits: AI Generated

Organoids have emerged as transformative tools in cancer research due to their ability to mimic the three-dimensional architecture and cellular complexity of human tumors more accurately than conventional two-dimensional cell cultures. Despite their biological fidelity, scaling organoid production and analysis while maintaining consistency and speed has remained elusive. The newly developed platform addresses these limitations by integrating extrusion bioprinting, which fabricates uniform tumor organoids embedded within extracellular matrix constructs tailored for multiwell plate formats. This advancement ensures high-throughput generation of physiologically relevant tumor models suitable for comprehensive drug screening.

One of the defining features of this platform is its reliance on label-free quantitative phase imaging, a high-speed optical technique that captures intrinsic properties of living cells without the need for fluorescent or chemical dyes. This allows continuous, non-invasive monitoring of organoid biomass changes and growth dynamics over extended periods, providing vital insights into tumor fitness and treatment-induced alterations. The avoidance of staining protocols circumvents the potential perturbations and temporal limitations associated with traditional destructive assays, thereby enabling more accurate longitudinal studies of tumor response.

To handle the enormous volumes of complex imaging data generated during these monitoring sessions, the researchers incorporated advanced computational methodologies, including automated image reconstruction and deep learning-based segmentation. This enables precise delineation of individual organoids and their morphological features across thousands of samples. Subsequently, machine learning algorithms track the temporal evolution of each organoid’s response to diverse drug treatments, quantifying heterogeneity within tumor populations and unmasking subtle differences that could dictate therapeutic efficacy or resistance.

This comprehensive analytical framework was rigorously validated using both established cancer cell lines and patient-derived tumor samples, successfully capturing dynamic responses to a variety of clinically relevant chemotherapeutic compounds. By transcending the traditional bulk average responses, the system pinpoints discrete organoid subsets exhibiting sensitivity or resistance, thereby refining the resolution of drug response assessments. This granular perspective facilitates the identification of rare, treatment-refractory tumor cell populations which are often responsible for therapeutic failure and disease relapse.

Dr. Michael Teitell, the director of the UCLA Health Jonsson Comprehensive Cancer Center and a co-senior author of the study, emphasized the platform’s transformative potential. He highlighted how this technology allows researchers to move beyond averaged drug efficacy metrics, instead illuminating the heterogeneous landscape of tumor cell drug responses at a single-organoid level. This capability to dissect tumor complexity lays the groundwork for unraveling underlying biological mechanisms governing differential treatment responses, which can guide the development of more targeted and effective therapeutic strategies.

Integral to this study is the platform’s capability to generate high-quality datasets amenable to large-scale analysis. By leveraging artificial intelligence, the system can process and interpret multifaceted phenotypic data, thus enabling simultaneous screening of hundreds of drug candidates. This scalability accelerates the pace of drug discovery by swiftly identifying promising therapeutic agents and combinations, particularly for cancers that currently lack robust treatment options. The ability to evaluate organoid responses in a high-throughput manner heralds a significant leap forward for translational oncology research.

Beyond its research applications, the platform holds tremendous promise for clinical oncology. When applied to patient-derived tumor cells, it offers a novel avenue for personalized treatment planning by preemptively testing the efficacy of various drugs on a patient’s own tumor organoids prior to therapy initiation. This approach could minimize the uncertainty inherent in current cancer treatment regimens and reduce exposure to ineffective therapies, thereby enhancing patient outcomes and quality of life — especially for those afflicted with rare or treatment-resistant malignancies.

The incorporation of advanced automated imaging and AI-powered analytical tools in this platform addresses several critical barriers that have historically impeded the integration of organoid models into clinical decision-making. Key among these are the challenges of maintaining biological accuracy while achieving experimental throughput and real-time data acquisition. By harmonizing these factors, the research team has crafted a versatile and robust workflow that is not only poised to revolutionize laboratory investigations but also to inform precision medicine initiatives.

The collaborative nature of this research extends beyond UCLA, with contributions from experts at institutions such as the University of Colorado School of Medicine and Virginia Commonwealth University’s Massey Comprehensive Cancer Center. The multidisciplinary team, combining expertise in pathology, laboratory medicine, bioengineering, and computational sciences, exemplifies the integrative approach necessary to tackle the complexity of cancer biology and translate technological advances into tangible clinical benefits.

Financial support for this pioneering work came from several prestigious entities including the Air Force Office of Scientific Research, the U.S. Department of Defense, the National Science Foundation, and the National Institutes of Health. Such diverse funding underscores the broader recognition of the importance of advanced technological platforms that integrate biology with AI to combat cancer, one of the most formidable health challenges globally.

In summary, this innovative platform heralds a new era in cancer research and treatment by providing an unparalleled toolset to observe, quantify, and predict tumor responses to therapy with extraordinary precision and scale. It embodies a fusion of 3D bioprinting, sophisticated label-free imaging, and artificial intelligence, collectively empowering researchers and clinicians to unravel tumor heterogeneity, uncover mechanisms of drug resistance, and ultimately refine personalized treatment strategies for patients facing challenging cancer diagnoses.

Subject of Research: Development of an integrated 3D bioprinting and AI-based platform for monitoring cancer tumor organoid responses to therapy.

Article Title: Not specified in the provided content.

News Publication Date: Not specified in the provided content.

Web References:
– UCLA Health Jonsson Comprehensive Cancer Center: https://www.uclahealth.org/cancer
– Nature Protocols article: https://www.nature.com/articles/s41596-026-01375-5

References:
Wang, B., Tebon, P., Nguyen, T., Sartini, S., Murray, G., Guest, D., Reed, J., Soragni, A., & Teitell, M. (2026). [Article Title]. Nature Protocols. DOI: 10.1038/s41596-026-01375-5.

Image Credits: Not provided.

Keywords: Organoids, Cancer, Cancer research, 3D bioprinting, Quantitative phase imaging, Artificial intelligence, Tumor heterogeneity, Personalized medicine, Drug screening, High-throughput screening.

The Pershing Square Foundation, renowned for backing visionary cancer research endeavors, instituted the Lotus Awards in 2025 to propel advancements specifically in ovarian cancer research. These grants, which amount to $750,000 over three years, are allocated to scientists whose projects demonstrate scientific rigor, originality, and the potential to drive significant clinical impact. Among eight distinguished awardees this year, Dr. Landau’s project stood out for its ambitious approach toward exploiting molecular vulnerabilities unique to ovarian cancer cells.

Ovarian cancer remains a formidable adversary in oncology due to its insidious onset and the absence of distinct symptoms in early stages. This stealthy nature often results in diagnoses only when the disease has advanced, complicating treatment efforts. Despite recent gains made through targeted therapies and immunotherapies, the mortality rate remains stubbornly high. There is an urgent need for novel interventions grounded in a deeper molecular understanding of ovarian malignancies.

At the heart of Dr. Landau’s research lies the application of next-generation single-cell profiling technologies. These techniques enable the dissection of tumor heterogeneity and cellular dynamics at an unprecedented resolution. By analyzing individual cancer cells, the team aims to unravel the complex molecular transformations that facilitate oncogenesis in ovarian tissue. This granular perspective is essential for pinpointing alterations that could be exploited as therapeutic targets.

A central focus of the investigation is the dysregulation of gene-activity control mechanisms during malignant transformation. Normally, cells maintain tightly regulated gene expression patterns to preserve homeostasis. However, cancerous cells often exhibit a breakdown in these controls, leading to unchecked proliferation and additional anomalies. Among these are the aberrant activation of transposable elements—mobile DNA sequences colloquially known as “jumping genes”—and defects in RNA splicing machinery that adversely affect protein synthesis fidelity.

Transposable elements have long been regarded as genomic parasites, but their reactivation in cancer can generate novel molecular signatures recognizable by the immune system. This phenomenon offers a tantalizing opportunity to design immunotherapies aimed at these cancer-specific molecular markers. Parallel to this, changes in RNA splicing can produce cancer-specific protein isoforms that do not exist in normal cells, further enriching the pool of potential immunotherapeutic targets.

Dr. Landau’s team intends to harness their advanced profiling platforms to characterize these anomalies comprehensively. By delineating the cancer-specific variants derived from both transposable element dysregulation and aberrant splicing, they hope to create a catalog of unique molecular targets. These targets could be exploited by sophisticated immune-based therapies, such as T-cell receptor-engineered treatments capable of selectively eradicating ovarian cancer cells while sparing healthy tissue.

The implications of this research extend beyond mere identification of biomarkers. It represents a paradigm shift toward personalized immunotherapy strategies, utilizing the tumor’s own molecular idiosyncrasies against it. This precision approach may overcome the limitations of current therapies, which often struggle with tumor heterogeneity and immune escape mechanisms.

Dr. Landau emphasized the transformative potential of these discoveries for patients battling ovarian cancer, a disease that has seen relatively little progress compared to other malignancies. His laboratory’s integrated approach—combining cutting-edge genomics, molecular biology, and immunology—reflects the forward-thinking interdisciplinary efforts necessary to tackle complex diseases.

Moreover, his affiliation as a core faculty member at the New York Genome Center provides access to collaborative networks and technological resources crucial for this ambitious project. This synergy of expertise and infrastructure accelerates the translation of benchside discoveries to bedside applications.

Ultimately, this award not only acknowledges Dr. Landau’s scientific excellence but also highlights the critical need for renewed focus on ovarian cancer research. It serves as a beacon of hope for the development of innovative immunotherapies that could drastically improve patient outcomes and survival rates.

The study’s methodological rigor and innovative use of single-cell technologies to dissect genomic and transcriptomic abnormalities reinforce the growing consensus that precision medicine is the future of oncology. As these efforts progress, they could drastically reshape the therapeutic landscape of ovarian cancer, ushering in a new era of tailored and effective immunotherapeutic interventions.

Subject of Research: Novel immunotherapy targets for ovarian cancer focusing on transposable element dysregulation and RNA splicing anomalies.
Article Title: Not specified.
News Publication Date: Not specified.
Web References: Not specified.
References: Not specified.
Image Credits: Not specified.
Keywords: Ovarian cancer, immunotherapy, transposable elements, RNA splicing, single-cell profiling, precision medicine, cancer research, T-cell therapy, molecular oncology.

One particularly promising investigation has developed radioactive gold nanoparticles engineered to selectively target the Epidermal Growth Factor Receptor (EGFR), a protein notoriously overexpressed in glioblastoma tumors, the most aggressive and lethal type of brain cancer. In preclinical mouse models, these targeted nanoparticles demonstrate remarkable tumor localization, minimizing off-target effects and toxicity. Their presence within tumor tissue markedly slows tumor progression and extends survival, underscoring a therapeutic potential that surpasses conventional treatments and non-targeted nanoparticles. This work paves the way for refined nanomedicine interventions in neuro-oncology.

Further enhancing the tools available for neurological research, another study unveils an ultra-high-resolution Positron Emission Tomography (PET) scanner capable of discerning anatomical structures smaller than half a millimeter. This unprecedented spatial resolution offers detailed visualization of the mouse brain’s intricate neuroanatomy. By employing a tracer aimed at metabotropic glutamate receptor subtype 1, researchers have validated the imaging against autoradiography, which is long regarded as a gold standard. The innovation provides a potent platform for elucidating pathophysiologic mechanisms underlying neurological disorders at an extraordinary level of detail in preclinical investigations.

On the frontier of oncologic imaging, a prospective clinical study assessing somatostatin receptor expression in metastatic extrapulmonary neuroendocrine carcinomas reveals a striking heterogeneity. Utilizing ^68Ga-DOTATATE PET scans alongside the more traditional ^18F-FDG PET, investigators documented that only a minority of these rare, aggressive cancers exhibit uniform and intense receptor uptake. This nuanced understanding challenges previous assumptions and informs clinicians about the molecular characteristics that may influence prognosis and therapeutic responsiveness in these malignancies.

In pediatric epilepsy, diagnostic challenges often arise when MRI scans fail to reveal definitive lesions. Researchers have demonstrated that integrating ^18F-FDG PET with MRI substantially improves the detection of metabolic abnormalities indicative of seizure-generating brain regions. In children suffering from focal epilepsy with negative or inconclusive MRI findings, this hybrid imaging modality significantly enriches the precision of lesion localization. Such advancements have profound implications for refining surgical interventions aimed at achieving seizure control, thereby improving quality of life in young patients.

Probing the biological effects of cutting-edge cancer therapies, scientists utilized total-body PET/CT scanners capable of near-room sensitivity to monitor proton therapy’s systemic impacts at ultra-low radioactive signal levels. This technology facilitated visualization of protons’ biologic activity as it courses through the circulatory system post-treatment. By capturing dynamic biodistribution patterns in real time, this approach offers unparalleled insights into the molecular and physiologic responses elicited by proton therapy, potentially guiding adaptive treatment strategies and enhancing therapeutic efficacy.

Prostate cancer management stands to benefit significantly from enhanced molecular imaging techniques. A comparative clinical analysis involving 102 men with oligometastatic castration-resistant prostate cancer highlights that PSMA PET/CT-guided metastasis-directed therapies extend intervals before biochemical progression compared to approaches using choline PET/CT or traditional imaging. This evidence firmly establishes the superior sensitivity and specificity of PSMA PET imaging, which now integrates into personalized treatment algorithms, offering hope for improved disease control in advanced prostate cancer patients.

Delving deeper into prostate cancer biology, investigators have synthesized a novel PET tracer with high affinity for androgen receptors, which are key drivers of tumor proliferation and resistance to therapy. Preclinical studies demonstrate that this tracer not only binds robustly and selectively to target receptors but also exhibits remarkable metabolic stability and tumor-specific uptake. By outperforming existing agents, this tracer introduces a new paradigm for studying androgen receptor dynamics, facilitating therapeutic monitoring and potentially guiding the development of targeted therapies in prostate malignancies.

Collectively, these studies epitomize the burgeoning synergy between molecular imaging, nanotechnology, and theranostics, culminating in a new era of diagnostic and therapeutic precision. The growing sophistication of PET imaging modalities and tracer design empowers researchers and clinicians to visualize biologic processes at an unprecedented scale and to intervene more effectively. This translational research fuels optimism for transforming outcomes in intractable neurological and oncologic diseases.

In summary, the advances showcased in The Journal of Nuclear Medicine underscore a holistic evolution in nuclear medicine’s capability to characterize disease biology intricately and to enable interventions finely tuned to individual patient profiles. Whether detecting microscopic epilepsy lesions, tracking innovative nanoparticle therapeutics, or refining prostate cancer treatment paradigms, these developments exemplify the promise of precision medicine—a frontier rapidly being actualized through visionary research and cutting-edge technology.

The field anticipates that ongoing innovations in total-body imaging and receptor-targeted radiotracers will further unravel complex disease mechanisms while simultaneously optimizing patient-specific care. As nuclear medicine evolves from purely diagnostic imaging to integral roles in tailored theranostic strategies, patient outcomes are poised to reach new heights, offering hope in battling some of the most challenging medical conditions today.

The Society of Nuclear Medicine and Molecular Imaging continues to spearhead this transformative journey by disseminating these critical findings to the global medical community, fostering collaboration, and expediting translation from bench to bedside. Practitioners, researchers, and stakeholders eagerly await future developments building upon these pioneering achievements which collectively reimagine the horizons of precision diagnostics and targeted therapy.

Subject of Research:
Advances in molecular imaging and targeted therapies in neuro-oncology, epilepsy, neuroendocrine cancers, proton therapy monitoring, and prostate cancer.

Article Title:
Multiple groundbreaking studies published in The Journal of Nuclear Medicine highlight innovations in targeted radioactive nanoparticles, ultra-high-resolution PET imaging, receptor-specific tracers, and comprehensive therapeutic monitoring.

News Publication Date:
June 12, 2026

Web References:
https://doi.org/10.2967/jnumed.125.271785
https://doi.org/10.2967/jnumed.125.271600
https://doi.org/10.2967/jnumed.125.271460
https://jnm.snmjournals.org/content/early/2026/06/11/jnumed.125.271155
https://doi.org/10.2967/jnumed.126.272338
https://doi.org/10.2967/jnumed.125.271680
https://doi.org/10.2967/jnumed.125.271531

Keywords:
Molecular imaging, Positron emission tomography, Targeted nanoparticles, Glioblastoma, Neuroendocrine carcinoma, Epilepsy, Proton therapy, Prostate cancer, PSMA PET/CT, Androgen receptor imaging, Theranostics, Precision medicine

Liquid biopsies have emerged as a minimally invasive method to analyze cell-free DNA (cfDNA) fragments shed by tumors into the bloodstream. This approach has revolutionized cancer diagnostics by enabling continuous monitoring of tumor genomics without the need for traditional tissue biopsies. However, one grave challenge persists: the high background noise stemming from mutations accumulated in white blood cells through clonal hematopoiesis. This confounding signal often leads to ambiguity in discerning whether detected mutations truly originate from tumor cells or from aging-related alterations in blood cells, complicating therapeutic choices.

The plasmaCHORD model ingeniously tackles this challenge by scrutinizing distinct fragmentation patterns of cfDNA. Tumor-derived DNA fragments and those from white blood cells undergo differential cleavage processes, resulting in unique cfDNA fragmentation profiles. By leveraging these patterns alongside patient-specific variables such as age, gene involved, and mutation characteristics, the algorithm accurately predicts the source of each mutation. This nuanced analysis goes well beyond traditional sequencing, which often treats detected mutations without contextual origin differentiation.

Training plasmaCHORD involved the comprehensive analysis of liquid biopsy data from 225 patients afflicted with a variety of solid tumors including breast, colorectal, esophageal, ovarian, and non-small cell lung cancers. The model’s predictive power was rigorously validated using matched tumor biopsy and white blood cell sequencing, guaranteeing that the classification of mutation origins was grounded in unequivocal biological evidence. The initial results revealed a marked improvement in correctly identifying tumor mutations, setting a new benchmark for clinical molecular diagnostics.

To test the model’s robustness, the research team applied plasmaCHORD to an independent cohort comprising 114 patients with breast, prostate, or non-small cell lung cancers sourced from a different institution employing a different liquid biopsy sequencing technology. Remarkably, the tool maintained similar accuracy, distinguishing tumor mutations from hematopoietic mutations with high fidelity. PlasmaCHORD boosted the accuracy rates from a near-coin-flip 50% baseline to an impressive 83% for key mutations with clinical significance, underscoring its potential for widespread clinical adoption.

Clinically, this innovation transcends theoretical modeling, as demonstrated through its deployment within the Johns Hopkins Molecular Tumor Board. Integrating plasmaCHORD’s predictions enabled clinicians to circumvent the pitfall of selecting ineffective treatments driven by misattributed mutations. By ensuring that only tumor-specific mutations guide therapeutic decisions, the model optimizes patient outcomes, potentially reducing unnecessary drug exposure and associated toxicities. This synergy of artificial intelligence and clinical oncology epitomizes the future of personalized cancer treatment.

One-third of mutations identified in tumor-naive liquid biopsies are believed to stem from white blood cells — a statistic that has long hindered the clinician’s ability to tailor precision therapies based on liquid biopsy results alone. By incorporating plasmaCHORD into the diagnostic workflow, oncologists gain an unprecedented clarity to confidently target mutations that genuinely underpin the patient’s malignancy, thereby reinforcing the integral link between molecular profiling and precision therapy.

The impetus behind plasmaCHORD is grounded in a deep understanding of cfDNA biology. DNA fragments circulating in the blood originate from multiple physiological processes, each imparting distinct fragmentation signatures. Tumor cells often release DNA with specific sizes and cleavage patterns due to apoptosis and necrosis mechanisms distinct from those active in hematopoietic cells. Capturing these fragmentation nuances enables plasmaCHORD to function as a molecular detective, distinguishing subtle signals in a complex cfDNA milieu.

The Johns Hopkins research team led by co-authors Jenna Canzoniero, M.D., M.S., and Valsamo Anagnostou, M.D., Ph.D., envisions that future iterations of plasmaCHORD will refine predictive accuracy even further. Plans are underway to integrate additional genomic and epigenomic features, as well as to validate the model across larger and more diverse populations. Such advances will pave the way for plasmaCHORD to be seamlessly embedded into routine clinical workflows and multi-institutional cancer genomic databases.

Collaborative efforts across multiple academic and industry institutions, including Vanderbilt University, LabCorp, and the Netherlands Cancer Institute, underscore the broad interest and trust in plasmaCHORD’s transformative potential. Funding from prestigious bodies such as the National Cancer Institute and the Department of Defense reflects the critical importance of this research to national cancer control priorities and the future of cancer care innovation.

The advent of plasmaCHORD exemplifies how artificial intelligence can unravel complex biological signals obscured by noise, delivering enhanced diagnostic precision. As liquid biopsies continue to gain prominence, tools like plasmaCHORD will be instrumental not only in honing treatment selection for individual patients but also in accelerating research toward overcoming cancer’s evolving genetic landscape.

In summary, plasmaCHORD stands as a beacon of progress in the quest to decode the biological origin of cfDNA mutations. By marrying novel machine learning algorithms with deep molecular understanding, it elevates liquid biopsy from a promising concept to a powerful clinical utility, allowing oncologists to focus precisely on the genetic hallmarks of tumors and tailor therapies with newfound confidence and accuracy.

Subject of Research: Application of machine learning to improve mutation source identification in liquid biopsies for cancer diagnosis and treatment.

Article Title: Development of an artificial intelligence method to accurately characterize mutations in liquid biopsies

News Publication Date: May 1, 2024

Web References:
https://doi.org/10.1158/1078-0432.CCR-25-0976
https://www.hopkinsmedicine.org/kimmel-cancer-center

Image Credits: Valsamo Anagnostou/ChatGPT

Keywords: Liquid biopsy, cell-free DNA, plasmaCHORD, machine learning, clonal hematopoiesis, cancer diagnostics, mutation characterization, precision oncology, molecular tumor board

One of the most pivotal contributions comes from the clinical trials led by Dr. Janice Mehnert, which explore innovative adjuvant therapies in Merkel cell carcinoma (MCC), a notoriously aggressive and rare skin cancer. Her randomized Phase 3 trial, known as EA6174 or STAMP, investigated the postoperative efficacy of pembrolizumab, an immune checkpoint inhibitor, in preventing cancer recurrence. Although the overall relapse-free survival improvement narrowly missed statistical significance, the dramatic reduction in distant metastatic progression heralds a potential paradigm shift in MCC management, particularly when paired with radiation therapy administered prior to immunotherapy initiation. This nuanced sequencing effect demands further exploration to optimize therapeutic windows and survival benefits.

In an extensive epidemiological study on lung cancer, Dr. Daniel J. Becker and colleagues have illuminated the troubling socio-economic inequities that persist following the introduction of U.S. Preventive Services Task Force (USPSTF) screening guidelines in 2013. By harnessing a comprehensive national database encompassing nearly one million cases over nearly two decades, their analysis reveals that earlier-stage lung cancer detection and survival have improved broadly, yet the gains disproportionately favor wealthier populations. The widening survival gap underscores systemic barriers in healthcare access, screening uptake, and post-diagnosis supportive infrastructure, calling for targeted policies to bridge these disparities and democratize the benefits of early intervention.

Turning to prostate cancer, cutting-edge computational biology methodologies have ushered in a new era of prognostication for metastatic castration-resistant prostate cancer (mCRPC). Led by Dr. David R. Wise, researchers have developed a machine-learning model that integrates transcriptional regulatory activity with genomic alterations and clinical variables, outperforming conventional gene expression signatures. This biologically informed approach elucidates complex tumor phenotypes associated with aggressive and treatment-resistant disease states. Such integrative models offer promise not only in refining risk stratification but also in guiding personalized therapeutic strategies that can dynamically adapt to tumor evolution and heterogeneity.

Meanwhile, immunotherapy timing emerges as a critical variable affecting patient outcomes in triple-negative breast cancer (TNBC). A retrospective cohort analysis spearheaded by Dr. Iris Zhi at Perlmutter Cancer Center-Long Island evaluated the circadian impact of immune checkpoint blockade infusion schedules on neoadjuvant treatment efficacy. The data suggest that earlier administration of immunotherapy doses correlates with significantly reduced recurrence risk and improved pathological complete response rates. These findings hint at the profound influence of circadian biology on immune system modulation and highlight the potential clinical utility of chronotherapy frameworks to heighten immunotherapeutic effectiveness in aggressive breast cancers.

In the realm of cellular therapies, the ongoing phase 1/2 EVEREST-2 trial introduces an innovative “logic-gated” CAR T-cell platform, A2B543, targeted against mesothelin-expressing solid tumors. Dr. Salman R. Punekar reported that this investigational approach seeks to balance tumor specificity and safety by integrating multi-input gating mechanisms designed to limit off-tumor toxicity, a persistent challenge that has impeded CAR T-cell expansion beyond hematologic malignancies. Early safety and tolerability outcomes are promising, and the trial’s multi-cohort enrollment encompassing pancreatic, ovarian, lung, and colorectal cancers could significantly broaden CAR T-cell application horizons if efficacy is demonstrated.

Central to all these endeavors is the Perlmutter Cancer Center’s integrated precision oncology model, which synergizes clinical care, molecular research, and bioinformatics expertise. This collaborative ecosystem empowers clinicians and scientists to accelerate translational discoveries and deliver personalized interventions that adapt to tumor biology and patient heterogeneity. Dr. Anirban Maitra, director of the center, emphasizes the imperative of multidisciplinary teamwork in propelling clinical innovation and ensuring equitable patient access to cutting-edge therapies and clinical trials.

Moreover, the research presented at ASCO 2026 collectively stresses the dual importance of biological complexity and social determinants in shaping cancer outcomes. While advances in molecular characterization and targeted therapies herald improved survival for many, disparities persist at the population level due to socio-economic factors that limit screening access, diagnostic precision, and comprehensive care. Strategies integrating technological innovations with public health interventions are urgently needed to close these gaps and ensure all patients benefit from progress.

The detailed investigations into prognostic biomarkers, immune modulation timing, and novel therapeutic constructs reflect a broader shift towards systems biology-informed oncology. By deciphering gene regulatory networks and temporal treatment dynamics, researchers are refining therapeutic windows and identifying combinatorial strategies that mitigate resistance and optimize efficacy. These multidisciplinary studies not only expand the scientific frontier but also translate into actionable clinical innovations for patients with rare tumors and advanced disease.

NYU Langone Health’s commitment extends beyond research to education and dissemination, with faculty leading numerous poster presentations and educational sessions at the ASCO meeting. The breadth and depth of their work convey a robust pipeline of discovery from bench to bedside. As these emerging data integrate into clinical practice guidelines, they hold the potential to improve survival outcomes and quality of life for diverse patient populations facing formidable cancer diagnoses.

The momentum generated at ASCO by Perlmutter Cancer Center’s research exemplifies the transformative potential of precision medicine in oncology. By leveraging genomic insights, immunological timing, and advanced therapeutics, these efforts are redefining the contours of cancer treatment. The promising early results encourage continued clinical trial enrollment and multidisciplinary collaboration, paving the way for a new standard of care that is both scientifically sophisticated and deeply patient-centered.

Subject of Research: Advances in cancer treatment and disparities in oncology outcomes including Merkel cell carcinoma, lung cancer screening disparities, metastatic castration-resistant prostate cancer prognostication, triple-negative breast cancer immunotherapy timing, and novel CAR T-cell therapies for solid tumors.

Article Title: NYU Langone Health’s Perlmutter Cancer Center Unveils Transformative Oncology Research at ASCO 2026

News Publication Date: 2026

Web References:

• https://nyulangone.org/locations/perlmutter-cancer-center
• https://nyulangone.org/doctors/1962617472/janice-mehnert
• https://nyulangone.org/doctors/1639361546/daniel-j-becker
• https://nyulangone.org/doctors/1336438258/david-r-wise
• https://nyulangone.org/doctors/1548573660/iris-zhi
• https://nyulangone.org/doctors/1730454034/salman-r-punekar

Keywords: Cancer research, Merkel cell carcinoma, pembrolizumab, lung cancer screening disparities, metastatic castration-resistant prostate cancer, prognostic biomarkers, triple-negative breast cancer, immunotherapy timing, CAR T-cell therapy, solid tumors, NYU Langone Health, Perlmutter Cancer Center, ASCO 2026

Chromosomal instability, a hallmark of cancer, embodies frequent alterations in chromosome number and structure, fostering genomic chaos that accelerates tumor progression and therapeutic resistance. Recognizing this, researchers harnessed large-scale transcriptome sequencing datasets to explore a robust gene signature linked to CIN, with the goal of refining prognostic models and illuminating the intricate interplay between genomic instability and immune microenvironments.

Leveraging the well-established CIN25 gene signature as a foundation, the investigators employed unsupervised consensus clustering to dissect breast cancer samples into distinct molecular subgroups. This technique enabled the capture of heterogeneity in chromosomal instability patterns across diverse patient cohorts. Following this, advanced statistical modeling approaches, notably LASSO (Least Absolute Shrinkage and Selection Operator) and rigorous multivariate Cox proportional hazards regression, were utilized to refine the gene panel. This meticulous process yielded a streamlined 13-gene prognostic model, aptly termed the “CIN score,” designed for clinical applicability and predictive precision.

The clinical implications of the CIN score proved profound upon validation in multiple patient cohorts. Individuals classified within the high CIN score group exhibited markedly worse overall survival outcomes, underscoring the score’s capacity to identify aggressive breast cancer phenotypes. Additionally, these patients displayed unfavorable clinicopathological characteristics, affirming the CIN score’s utility as a composite biomarker integrating tumor biology and clinical factors.

Beyond prognosis, the study pioneered an investigation into the association of the CIN score with the tumor immune microenvironment. Multi-omics analyses and single-cell RNA sequencing (scRNA-seq) illuminated striking differences in immune cell infiltration patterns between groups stratified by CIN score. The low-CIN score subgroup was characterized by an immune milieu abundant in activated anti-tumor effectors, particularly CD8+ cytotoxic T lymphocytes and mature dendritic cells—both pivotal players in orchestrating effective immune responses against malignancies.

Concomitantly, this group exhibited enhanced expression of quintessential immune checkpoint molecules such as PD-1 and CTLA-4, which play critical roles in immune modulation and serve as therapeutic targets for immune checkpoint blockade therapies. This suggests that patients with lower CIN burden may experience more favorable responses to emerging immunotherapies, highlighting the clinical resonance of the CIN score in treatment stratification.

Conversely, tumors classified with a high CIN score demonstrated pronounced immunosuppressive landscapes. These microenvironments featured dominant stromal interactions, notably via vascular endothelial growth factor (VEGF) signaling pathways, which are known to facilitate tumor angiogenesis, immunosuppression, and metastatic dissemination. The amplification of such pathways underscores the aggressive biology inherent to tumors with elevated chromosomal instability and underscores the necessity for combinatory therapeutic approaches.

Complementing immune landscape analyses, comprehensive drug sensitivity profiling uncovered that high CIN score tumors possess formidable resistance profiles against multiple frontline therapeutic agents, including chemotherapeutics like paclitaxel and cisplatin, as well as endocrine therapies exemplified by tamoxifen. These findings reveal the CIN score’s dual role not only as a prognostic biomarker but also as a predictive tool for treatment resistance, which could inform the selection of alternative or adjunctive treatments to overcome refractory disease.

Despite the promising revelations and robust correlative data, the authors advocate the need for further validation through large-scale, prospective, multicenter clinical trials to solidify the clinical implementation of the CIN score. Such trials will be critical to assess reproducibility, longitudinal stability, and the integration of this biomarker within existing clinical workflows.

In summary, this landmark study deftly establishes the CIN score as a novel integrative biomarker that synthesizes genomic instability parameters with immune profiling insights to enhance the granularity of breast cancer patient stratification. By elucidating the connections between chromosomal chaos, immune dynamics, and therapeutic vulnerabilities, the CIN score exemplifies a paradigm shift towards more precise and personalized oncology. Its adoption promises advances in risk prediction, prognostication, and therapeutic guidance, ultimately propelling the frontiers of precision medicine in breast cancer treatment landscapes.

As oncology continues to evolve in the molecular age, tools like the CIN score facilitate the tailoring of interventions to the individual tumor’s biological context, thereby optimizing patient outcomes and potentially circumventing the hurdles posed by tumor heterogeneity and immune evasion. This study exemplifies the fertile intersection of genomics, immunology, and clinical oncology, reinforcing the transformative potential embedded in multi-disciplinary cancer research.

Subject of Research: Breast Cancer Prognosis and Immunotherapy Response Using Chromosomal Instability-Based Gene Signature

Article Title: Leveraging a Chromosomal Instability-Based Signature to Predict the Prognosis and Immune Landscape of Breast Cancer

References: 10.1016/j.gendis.2025.101924

Image Credits: Huiling Wang, Huijuan Dai, Yaohui Wang, Qiong Wu, Mingxi Zhu, Wenjin Yin, Jinsong Lu

Keywords: Breast cancer, Chromosomal instability, CIN score, Immunotherapy, Prognostic biomarker, Tumor microenvironment, CD8+ T cells, Immune checkpoints, Drug resistance, Precision medicine

Central to the development and progression of numerous cancers are growth factor receptors—cell surface proteins that transmit extracellular signals to intracellular pathways, promoting proliferation and survival. Receptors such as the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2) have been implicated in lung, breast, and colorectal cancers, among others. Therapies targeting these molecules, including monoclonal antibodies and tyrosine kinase inhibitors, have transformed treatment paradigms. However, despite initial efficacy, the formidable adaptability of cancer cells frequently culminates in acquired drug resistance, limiting the long-term success of these interventions.

Addressing this critical barrier, a pioneering research team from the Harrington Discovery Institute at University Hospitals in Cleveland has made significant strides in decoding the cellular machinery that modulates growth factor receptor signaling. Their recently published study in Science Signaling elucidates the essential role of Golgi apparatus-associated proteins in orchestrating the trafficking and surface presentation of these receptors. This nuanced understanding offers a fresh vantage point on how cancer cells maintain and enhance oncogenic signaling networks.

The study spotlights the Golgi protein GOLPH3 and its interaction with the myosin motor protein MYO18A as integral components facilitating the movement of growth factor receptors from intracellular compartments to the cell membrane. This Golgi secretory machinery ensures proper receptor localization, a prerequisite for efficient activation by extracellular growth factors. Disruption of this circuitry impairs receptor signaling, thereby attenuating cancer cell proliferation and tumor growth. These findings illuminate previously unappreciated facets of cancer cell biology that extend beyond the receptor molecules themselves.

Moreover, the research delineates how aberrant expression and hyperactivation of GOLPH3 contribute to oncogenic receptor tyrosine kinase signaling across multiple human cancer types, including lung, breast, and colorectal carcinomas. By establishing a mechanistic link between Golgi-mediated trafficking and receptor-driven oncogenesis, the study provides compelling evidence for targeting this pathway therapeutically. Such strategies could potentially overcome or circumvent resistance to conventional receptor-targeted therapies.

The implications of this discovery are profound. Targeting the Golgi apparatus components involved in growth factor receptor trafficking could represent a novel class of anti-cancer agents, either as monotherapies or in combination with existing treatments. By interfering with receptor localization rather than receptor-ligand interactions, these strategies may evade common resistance mechanisms that cancer cells exploit. This approach exemplifies a shift towards targeting the cellular logistics underlying oncogenic signaling, an emerging frontier in cancer therapeutics.

From a technical perspective, the researchers employed sophisticated molecular biology techniques, including gene knockdown and protein interaction assays, to validate the functional roles of GOLPH3 and MYO18A. Complementing in vitro studies with analyses of human tumor samples, they confirmed the clinical relevance of their findings. This rigorous methodology underpins the translational potential of their work, bridging basic science and clinical application.

Dr. Seth J. Field, the study’s lead investigator and Chief Scientific Officer at the Harrington Discovery Institute, underscores the significance of the Golgi apparatus in cancer biology. Traditionally viewed as a cellular organelle dedicated to protein processing and sorting, the Golgi now emerges as a dynamic platform modulating oncogenic signals. This paradigm shift reinforces the importance of fundamental cell biology in unveiling innovative therapeutic targets.

Looking ahead, the research team aims to leverage these insights for drug development. The Harrington Discovery Institute, renowned for its mission to accelerate promising scientific discoveries into viable medicines, provides a fertile environment for this endeavor. The institute’s multidisciplinary approach, integrating drug discovery expertise and investment capital, accelerates the translation of novel targets like GOLPH3 and MYO18A into clinical candidates.

This breakthrough exemplifies how dissecting the intricacies of cellular trafficking can redefine cancer treatment landscapes. As resistance to targeted therapies remains a formidable obstacle, innovations that address the root causes of signaling persistence and adaptation are vital. The study’s findings pave the way for combination therapies that disrupt multiple nodes of oncogenic pathways, thereby enhancing therapeutic durability.

In summary, the research conducted by the Harrington Discovery Institute enriches our comprehension of cancer cell biology by identifying crucial Golgi-associated proteins that facilitate growth factor receptor signaling. This discovery not only elucidates mechanisms underpinning tumor progression and drug resistance but also unveils a promising reservoir of drug targets. Harnessing this knowledge stands to revolutionize cancer treatment, offering hope for more effective and sustained therapies against aggressive malignancies.

Subject of Research:
Article Title:
News Publication Date:
Web References:
References:
Image Credits:

Keywords: Cancer, Growth Factor Receptors, Golgi Apparatus, GOLPH3, MYO18A, Receptor Trafficking, Drug Resistance, Targeted Therapy, Oncology, Molecular Biology, Therapeutic Targets, Cancer Signaling

Dr. Slamon’s recognition stems from his extensive work in translational cancer research, where fundamental biological insights have directly informed clinical advances. His pioneering studies revealed the HER2 gene’s critical role in driving aggressive breast cancer subtypes, an insight that reshaped approaches towards diagnosis and treatment. By elucidating how HER2 gene overexpression contributes to tumor proliferation and poor prognosis, Slamon laid the groundwork for transforming breast cancer management from a conventional chemotherapeutic framework to one centered on precision medicine.

The cornerstone of Slamon’s career achievement lies in the development of trastuzumab, commercially branded as Herceptin. This monoclonal antibody therapy selectively targets the HER2 protein expressed on the surface of breast cancer cells in approximately 20% of patients worldwide, who face particularly aggressive disease courses. Herceptin functions by binding to the HER2 receptor, inhibiting downstream signaling pathways essential for tumor growth and survival, thereby offering a targeted therapeutic approach that spares normal cells and reduces systemic toxicity typical of traditional chemotherapy.

The advent of trastuzumab marked a paradigm shift, introducing the first FDA-approved biologic therapy specifically designed against a molecular cancer target. Its success not only improved survival in HER2-positive breast cancer patients but also affirmed the viability of targeted therapy, fundamentally changing clinical oncology practice. This breakthrough accelerated the development of additional HER2-targeted agents, such as pertuzumab, tucatinib, and neratinib, which have provided new combination regimens and expanded treatment options, improving outcomes even further.

Slamon’s research exemplifies translational medicine, bridging laboratory discoveries with therapeutic innovation. At UCLA’s Jonsson Comprehensive Cancer Center, his work emphasizes molecular mechanisms of oncogenesis, tumor microenvironment interactions, and mechanisms of drug resistance. Understanding resistance pathways has led to the rational design of next-generation inhibitors and combination strategies that aim to overcome or delay therapeutic failure, thus addressing clinical challenges such as metastasis and treatment-refractory disease.

Throughout his remarkable four decades at UCLA, Dr. Slamon’s contributions have garnered numerous accolades that underscore his scientific and clinical impact. Awards such as the Lasker-DeBakey Clinical Medical Research Award, the Gairdner International Award, and the Szent-Györgyi Prize reflect his global influence on cancer biology and treatment. His election to the National Academy of Inventors and designation among Forbes’ Greatest American Inventors further testify to his role as a leading innovator translating science into tangible health benefits.

At the mechanistic level, Slamon’s work dissected the HER2 receptor’s role as a member of the ErbB family of receptor tyrosine kinases, illuminating how receptor overactivation leads to uncontrolled cell proliferation. These findings illuminated signaling cascades involving pathways such as PI3K/AKT and MAPK/ERK, which are integral to malignant transformation and survival. Targeted blockade of these pathways via antibodies and tyrosine kinase inhibitors represents a blueprint extended to other cancers harboring actionable molecular drivers.

Moreover, the HER2 story catalyzed broader shifts in oncology drug development by validating biomarkers as predictive tools for therapeutic response. This precision oncology approach tailors treatment based on individual tumor biology, minimizing unnecessary toxicity and optimizing clinical benefit. Slamon’s foundational work thus propelled the emergence of companion diagnostics and fostered a new era in which cancer treatment became increasingly personalized and data-driven.

The ripple effects of HER2-targeted therapy extend beyond breast cancer. Agents stemming from the trastuzumab model have informed therapies in other malignancies, including colorectal, lung, and gastric cancers, where similar principles of receptor overexpression or mutation-driven growth exist. This broader applicability highlights the profound impact of Slamon’s contributions on the oncology landscape at large, illustrating how detailed molecular insights can revolutionize multiple fields.

Slamon’s election to the AAP also underscores the importance of collaborative scientific environments. Integral to his success has been the multidisciplinary synergy at UCLA and its cancer center, where basic scientists, translational researchers, and clinicians converge to translate bench discoveries into therapeutic realities. This culture of collaboration accelerates innovation and exemplifies how academic medical centers drive forward groundbreaking science and improve patient care.

His story is one of perseverance and vision, showing how decades of methodical research, clinical trials, and iterative refinement can culminate in treatments that save millions of lives. The introduction of HER2-targeted therapies has redefined prognosis for breast cancer patients, transforming what was once a dire diagnosis into a manageable condition with increasing long-term survival rates. Such achievements continue to inspire ongoing efforts toward curing cancer and improving quality of life worldwide.

Dr. Dennis Slamon’s legacy embodies the transformative power of translational medical research. His election to the Association of American Physicians is not only a personal honor but a testament to the enduring value of integrating basic science with clinical care to confront some of medicine’s most formidable challenges. As oncology continues to evolve toward more precise, immune-based, and combinatorial therapies, Slamon’s trailblazing work remains a foundational cornerstone guiding future innovation.

Subject of Research: Breast Cancer Molecular Biology and Targeted Therapy

Article Title: Pioneering Precision Oncology: Dr. Dennis Slamon’s Trailblazing Contributions to HER2-Targeted Breast Cancer Therapy

News Publication Date: 2024

Web References:

• https://www.uclahealth.org/providers/dennis-slamon
• https://www.uclahealth.org/cancer

Keywords: Breast cancer, HER2 gene, targeted therapy, trastuzumab, Herceptin, translational research, oncology, precision medicine, monoclonal antibody, molecular biology, cancer treatment, personalized medicine